Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Dec 15;98(12):2729–2738. doi: 10.1172/JCI119098

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C Serradeil-Le Gal 1, C Lacour 1, G Valette 1, G Garcia 1, L Foulon 1, G Galindo 1, L Bankir 1, B Pouzet 1, G Guillon 1, C Barberis 1, D Chicot 1, S Jard 1, P Vilain 1, C Garcia 1, E Marty 1, D Raufaste 1, G Brossard 1, D Nisato 1, J P Maffrand 1, G Le Fur 1
PMCID: PMC507737  PMID: 8981918

Abstract

SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human kidney (0.6 < or = Ki [nM] < or = 4.1). In this latter preparation, SR 121463A potently antagonized arginine vasopressin (AVP)-stimulated adenylyl cyclase activity (Ki = 0.26+/-0.04 nM) without any intrinsic agonistic effect. In autoradiographic experiments performed in rat kidney sections, SR 121463A displaced [3H]AVP labeling especially in the medullo-papillary region and confirmed that it is a suitable tool for mapping V2 receptors. In comparison, the nonpeptide V2 antagonist, OPC-31260, showed much lower affinity for animal and human renal V2 receptors and lower efficacy to inhibit vasopressin-stimulated adenylyl cyclase (Ki in the 10 nanomolar range). Moreover, OPC-31260 exhibited a poor V2 selectivity profile and can be considered as a V2/V1a ligand. In normally hydrated conscious rats, SR 121463A induced powerful aquaresis after intravenous (0.003-0.3 mg/kg) or oral (0.03-10 mg/kg) administration. The effect was dose-dependent and lasted about 6 hours at the dose of 3 mg/kg p.o. OPC-31260 had a similar aquaretic profile but with markedly lower oral efficacy. The action of SR 121463A was purely aquaretic with no changes in urine Na+ and K+ excretions unlike that of known diuretic agents such as furosemide or hydrochlorothiazide. In addition, no antidiuretic properties have been detected with SR 121463A in vasopressin-deficient Brattleboro rats. Thus, SR 121463A is the most potent and selective, orally active V2 antagonist yet described and could be a powerful tool for exploring V2 receptors and the therapeutical usefulness of V2 blocker aquaretic agents in water-retaining diseases.

Full Text

The Full Text of this article is available as a PDF (5.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ang V. T., Jenkins J. S. Neurohypophysial hormones in the adrenal medulla. J Clin Endocrinol Metab. 1984 Apr;58(4):688–691. doi: 10.1210/jcem-58-4-688. [DOI] [PubMed] [Google Scholar]
  2. Balment R. J., Brimble M. J., Forsling M. L. Oxytocin release and renal actions in normal and Brattleboro rats. Ann N Y Acad Sci. 1982;394:241–253. doi: 10.1111/j.1749-6632.1982.tb37432.x. [DOI] [PubMed] [Google Scholar]
  3. Birnbaumer M., Seibold A., Gilbert S., Ishido M., Barberis C., Antaramian A., Brabet P., Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992 May 28;357(6376):333–335. doi: 10.1038/357333a0. [DOI] [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  5. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  6. Chou C. L., DiGiovanni S. R., Luther A., Lolait S. J., Knepper M. A. Oxytocin as an antidiuretic hormone. II. Role of V2 vasopressin receptor. Am J Physiol. 1995 Jul;269(1 Pt 2):F78–F85. doi: 10.1152/ajprenal.1995.269.1.F78. [DOI] [PubMed] [Google Scholar]
  7. Diaz Brinton R., Brownson E. A. Vasopressin-induction of cyclic AMP in cultured hippocampal neurons. Brain Res Dev Brain Res. 1993 Jan 15;71(1):101–105. doi: 10.1016/0165-3806(93)90110-v. [DOI] [PubMed] [Google Scholar]
  8. Fushimi K., Uchida S., Hara Y., Hirata Y., Marumo F., Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 1993 Feb 11;361(6412):549–552. doi: 10.1038/361549a0. [DOI] [PubMed] [Google Scholar]
  9. Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin Chem. 1991 Oct;37(10 Pt 2):1828–1830. [PubMed] [Google Scholar]
  10. Goldsmith S. R., Dodge-Brown D. L., Katz A. Alpha 2-adrenergic stimulation and vasopressin in congestive heart failure. J Cardiovasc Pharmacol. 1989 Sep;14(3):425–429. doi: 10.1097/00005344-198909000-00011. [DOI] [PubMed] [Google Scholar]
  11. Gorbulev V., Büchner H., Akhundova A., Fahrenholz F. Molecular cloning and functional characterization of V2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur J Biochem. 1993 Jul 1;215(1):1–7. doi: 10.1111/j.1432-1033.1993.tb18000.x. [DOI] [PubMed] [Google Scholar]
  12. Guillon G., Butlen D., Cantau B., Barth T., Jard S. Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: relation to adenylate cyclase activation. Eur J Pharmacol. 1982 Dec 3;85(3-4):291–304. doi: 10.1016/0014-2999(82)90216-3. [DOI] [PubMed] [Google Scholar]
  13. Guillon G., Trueba M., Joubert D., Grazzini E., Chouinard L., Côté M., Payet M. D., Manzoni O., Barberis C., Robert M. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 1995 Mar;136(3):1285–1295. doi: 10.1210/endo.136.3.7867583. [DOI] [PubMed] [Google Scholar]
  14. Hirasawa A., Nakayama Y., Ishiharada N., Honda K., Saito R., Tsujimoto G., Takano Y., Kamiya H. Evidence for the existence of vasopressin V2 receptor mRNA in rat hippocampus. Biochem Biophys Res Commun. 1994 Dec 30;205(3):1702–1706. doi: 10.1006/bbrc.1994.2864. [DOI] [PubMed] [Google Scholar]
  15. Kinter L. B., Huffman W. F., Stassen F. L. Antagonists of the antidiuretic activity of vasopressin. Am J Physiol. 1988 Feb;254(2 Pt 2):F165–F177. doi: 10.1152/ajprenal.1988.254.2.F165. [DOI] [PubMed] [Google Scholar]
  16. Liard J. F. cAMP and extrarenal vasopressin V2 receptors in dogs. Am J Physiol. 1992 Dec;263(6 Pt 2):H1888–H1891. doi: 10.1152/ajpheart.1992.263.6.H1888. [DOI] [PubMed] [Google Scholar]
  17. Liu J. J., Chen J. R., Buxton B. B., Johnston C. I., Burrell L. M. Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin VIa receptor antagonist, on human arterial coronary bypass graft. Clin Sci (Lond) 1995 Nov;89(5):481–485. doi: 10.1042/cs0890481. [DOI] [PubMed] [Google Scholar]
  18. Lolait S. J., O'Carroll A. M., McBride O. W., Konig M., Morel A., Brownstein M. J. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992 May 28;357(6376):336–339. doi: 10.1038/357336a0. [DOI] [PubMed] [Google Scholar]
  19. László F. A., László F., Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991 Mar;43(1):73–108. [PubMed] [Google Scholar]
  20. Manning M., Sawyer W. H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J Recept Res. 1993;13(1-4):195–214. doi: 10.3109/10799899309073655. [DOI] [PubMed] [Google Scholar]
  21. Manning M., Sawyer W. H. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med. 1989 Dec;114(6):617–632. [PubMed] [Google Scholar]
  22. Morel A., O'Carroll A. M., Brownstein M. J., Lolait S. J. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 1992 Apr 9;356(6369):523–526. doi: 10.1038/356523a0. [DOI] [PubMed] [Google Scholar]
  23. Morel F., Imbert-Teboul M., Chabardès D. Receptors to vasopressin and other hormones in the mammalian kidney. Kidney Int. 1987 Feb;31(2):512–520. doi: 10.1038/ki.1987.30. [DOI] [PubMed] [Google Scholar]
  24. Mouillac B., Chini B., Balestre M. N., Elands J., Trumpp-Kallmeyer S., Hoflack J., Hibert M., Jard S., Barberis C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem. 1995 Oct 27;270(43):25771–25777. doi: 10.1074/jbc.270.43.25771. [DOI] [PubMed] [Google Scholar]
  25. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  26. Ohnishi A., Orita Y., Okahara R., Fujihara H., Inoue T., Yamamura Y., Yabuuchi Y., Tanaka T. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest. 1993 Dec;92(6):2653–2659. doi: 10.1172/JCI116881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ohnishi A., Orita Y., Takagi N., Fujita T., Toyoki T., Ihara Y., Yamamura Y., Inoue T., Tanaka T. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther. 1995 Feb;272(2):546–551. [PubMed] [Google Scholar]
  28. Ostrowski N. L., Young W. S., 3rd, Knepper M. A., Lolait S. J. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993 Oct;133(4):1849–1859. doi: 10.1210/endo.133.4.8404628. [DOI] [PubMed] [Google Scholar]
  29. Peter J., Burbach H., Adan R. A., Lolait S. J., van Leeuwen F. W., Mezey E., Palkovits M., Barberis C. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol. 1995 Oct;15(5):573–595. doi: 10.1007/BF02071318. [DOI] [PubMed] [Google Scholar]
  30. Pettibone D. J., Kishel M. T., Woyden C. J., Clineschmidt B. V., Bock M. G., Freidinger R. M., Veber D. F., Williams P. D. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues. Life Sci. 1992;50(25):1953–1958. doi: 10.1016/0024-3205(92)90524-s. [DOI] [PubMed] [Google Scholar]
  31. Prpić V., Green K. C., Blackmore P. F., Exton J. H. Vasopressin-, angiotensin II-, and alpha 1-adrenergic-induced inhibition of Ca2+ transport by rat liver plasma membrane vesicles. J Biol Chem. 1984 Feb 10;259(3):1382–1385. [PubMed] [Google Scholar]
  32. Rosenthal W., Seibold A., Antaramian A., Lonergan M., Arthus M. F., Hendy G. N., Birnbaumer M., Bichet D. G. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 1992 Sep 17;359(6392):233–235. doi: 10.1038/359233a0. [DOI] [PubMed] [Google Scholar]
  33. Schmidt A., Audigier S., Barberis C., Jard S., Manning M., Kolodziejczyk A. S., Sawyer W. H. A radioiodinated linear vasopressin antagonist: a ligand with high affinity and specificity for V1a receptors. FEBS Lett. 1991 Apr 22;282(1):77–81. doi: 10.1016/0014-5793(91)80448-c. [DOI] [PubMed] [Google Scholar]
  34. Serradeil-Le Gal C., Raufaste D., Marty E., Garcia C., Maffrand J. P., Le Fur G. Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059. Kidney Int. 1996 Aug;50(2):499–505. doi: 10.1038/ki.1996.341. [DOI] [PubMed] [Google Scholar]
  35. Serradeil-Le Gal C., Raufaste D., Marty E., Garcia C., Maffrand J. P., Le Fur G. Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem Biophys Res Commun. 1994 Feb 28;199(1):353–360. doi: 10.1006/bbrc.1994.1236. [DOI] [PubMed] [Google Scholar]
  36. Serradeil-Le Gal C., Wagnon J., Garcia C., Lacour C., Guiraudou P., Christophe B., Villanova G., Nisato D., Maffrand J. P., Le Fur G. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993 Jul;92(1):224–231. doi: 10.1172/JCI116554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Stassen F. L., Erickson R. W., Huffman W. F., Stefankiewicz J., Sulat L., Wiebelhaus V. D. Molecular mechanisms of novel antidiuretic antagonists: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J Pharmacol Exp Ther. 1982 Oct;223(1):50–54. [PubMed] [Google Scholar]
  38. Sugimoto T., Saito M., Mochizuki S., Watanabe Y., Hashimoto S., Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem. 1994 Oct 28;269(43):27088–27092. [PubMed] [Google Scholar]
  39. Sørensen J. B., Andersen M. K., Hansen H. H. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995 Aug;238(2):97–110. doi: 10.1111/j.1365-2796.1995.tb00907.x. [DOI] [PubMed] [Google Scholar]
  40. Thibonnier M., Auzan C., Madhun Z., Wilkins P., Berti-Mattera L., Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem. 1994 Feb 4;269(5):3304–3310. [PubMed] [Google Scholar]
  41. Tribollet E., Barberis C., Dreifuss J. J., Jard S. Autoradiographic localization of vasopressin and oxytocin binding sites in rat kidney. Kidney Int. 1988 May;33(5):959–965. doi: 10.1038/ki.1988.94. [DOI] [PubMed] [Google Scholar]
  42. Ufer E., Postina R., Gorbulev V., Fahrenholz F. An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS Lett. 1995 Mar 27;362(1):19–23. doi: 10.1016/0014-5793(95)00150-8. [DOI] [PubMed] [Google Scholar]
  43. Wathes D. C., Swann R. W., Birkett S. D., Porter D. G., Pickering B. T. Characterization of oxytocin, vasopressin, and neurophysin from the bovine corpus luteum. Endocrinology. 1983 Aug;113(2):693–698. doi: 10.1210/endo-113-2-693. [DOI] [PubMed] [Google Scholar]
  44. Williams P. D., Clineschmidt B. V., Erb J. M., Freidinger R. M., Guidotti M. T., Lis E. V., Pawluczyk J. M., Pettibone D. J., Reiss D. R., Veber D. F. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem. 1995 Nov 10;38(23):4634–4636. doi: 10.1021/jm00023a002. [DOI] [PubMed] [Google Scholar]
  45. Yamamura Y., Ogawa H., Chihara T., Kondo K., Onogawa T., Nakamura S., Mori T., Tominaga M., Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991 Apr 26;252(5005):572–574. doi: 10.1126/science.1850553. [DOI] [PubMed] [Google Scholar]
  46. Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787–791. doi: 10.1111/j.1476-5381.1992.tb09058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. de Keyzer Y., Auzan C., Lenne F., Beldjord C., Thibonnier M., Bertagna X., Clauser E. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett. 1994 Dec 19;356(2-3):215–220. doi: 10.1016/0014-5793(94)01268-7. [DOI] [PubMed] [Google Scholar]
  48. de Rouffignac C., Corman B., Roinel N. Stimulation by antidiuretic hormone of electrolyte tubular reabsorption in rat kidney. Am J Physiol. 1983 Feb;244(2):F156–F164. doi: 10.1152/ajprenal.1983.244.2.F156. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES